Target-based drug discovery (TDD) has been the standard in biopharma research for a generation. While tremendous progress has been made against numerous diseases, discovery continues to be complex and challenging. Discovering and advancing a drug based on TDD now takes an average of 10 years and nearly $2 billion.1) But only about 12 percent of drugs that enter clinical trials are ever approved. The rate is less than half that for cancer treatments. And especially in CNS, no breakthrough treatments for Alzheimer’s disease or ALS have been developed using target-based drug discovery. Now we need to explore therapeutic targets which have not been discovered or exploited yet.
We must do better.
Genuv addresses this challenge by starting the drug discovery process for CNS diseases with phenotypic drug screening. This approach dramatically increases the diversity of targets which hit substances engage with, and thus the chance of developing of first-in-class therapies.
More typically used in classical pharmacology, phenotypic drug discovery focuses on finding molecules that induce the desired changes in cells, leaving aside hypotheses about how they alter disease pathways. Phenotypic discovery is increasingly recognized as being responsible for more first-in-class drugs with novel mechanisms of action. 2) 3)
The ATRIVIEW® platform screens molecules for their impact on neural stem cells within a physiological environment that mimics the conditions of neurodegenerative diseases such as Alzheimer’s. We are leading the way in the discovery of substances that promote neuroprotection and neurogenesis.